- EQT Private Equity acquired Schülke in July 2020
- The transaction is expected to be completed in Q4 of 2023
- ATHOS is a Munich, Germany-based single-family office
EQT, via EQT VIII Fund (EQT Private Equity), has agreed to sell Schülke, a provider of infection prevention and treatment products for the healthcare industry, to a consortium led by ATHOS along with other co-investors such as Bitburger Holding.
The deal has an enterprise value of about €1.4 billion, according to a source close to the deal.
Schülke is headquartered in Norderstedt, Germany. The company supplies hospitals and other healthcare institutions with disinfectants and antisepsis products and sells to the pharmacy and direct patient care channels, as well as the global life science industry.
EQT Private Equity acquired Schülke in July 2020.
Schülke has delivered double digit annual revenue growth and almost doubled EBITDA in its core healthcare business under EQT Private Equity’s ownership, according to a release.
“In close partnership with the management team, we have transformed Schülke from a corporate subsidiary to a high-performing, stand-alone healthcare company,” said Matthias Wittkowski, partner within EQT Private Equity’s advisory team.
The transaction is subject to customary regulatory approvals and is expected to close in Q4 of 2023.
EQT Private Equity invests in healthcare, technology, services, and industrial technology sectors.
EQT is a global investment organisation that manages €119 billion in assets. The firm is based in Stockholm, Sweden.
ATHOS is a Munich, Germany-based single-family office.
EQT Private Equity was advised by Bank of America, Freshfields Bruckhaus Deringer, Deloitte and Bain & Company.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: 
